FDA advisory panel narrowly withholds support for AstraZeneca’s combo in breast cancer

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor

AstraZeneca wins US nod for at-home lupus treatment in major shift for SLE care

The approval was driven by data from the Phase III TULIP-SC trial

New support group targets delayed diagnosis of Vasculitis in India

Originally established in Punjab, the Vasculitis Society of India is now expanding its footprint nationwide

NHA convenes Chintan Shivir to accelerate Ayushman Bharat schemes

Focus on preventive, tech-driven healthcare and digital ecosystem reforms under AB PM-JAY and ABDM

Insmed’s Brensocatib fails to hit endpoints in hidradenitis suppurativa study

The results were consistent across both the 10 mg and 40 mg treatment arms

Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals

The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes

Roche’s experimental obesity drug shows strong weight-loss results in mid-stage trial

The company announced positive topline data from the Phase II ZUPREME-1 trial

Theravance Biopharma winds down Ampreloxetine programme after Phase 3 miss

SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026

During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions

Asahi Kasei secures global rights to novel Alchemedicine preclinical compounds

Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients